ClinicalTrials.gg
RecruitingNCT06964464CARVTOP-ICDUpdated Sep 18, 2025

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

A Phase 4 interventional study of Metoprolol Succinate and Carvedilol in Heart Failure With Reduced Ejection Fraction (HFrEF), Sudden Cardiac Death and Ventricular Arrhythmia, sponsored by University of Rochester. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by University of Rochester · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Death, Sudden, Cardiac with a site in United States — 23 open to participants now, 33 under way, 1 of them phase 3. Death, Sudden, Cardiac · United States.

Planned enrollment
5th of 54
2,000 · median 88
Started
2025
with 4 others
Phase 4
4 of 112
1 open now
Primary completion
2031-06
later than 30 of 32 live
Registered
108th of 112
by date

Among the 112 studies in Death, Sudden, Cardiac with a site in United States, this one is the 5th largest by planned enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 30 of the 32 other live ones, and was the 108th registered.

Death, Sudden, Cardiac

364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.

Browse Death, Sudden, Cardiac studies →

Open to participants now

23 of the 112 studies in Death, Sudden, Cardiac with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Death, Sudden, Cardiac with a site in United States, or all of them as a file.
02

Study summary

This prospective, multicenter, open-label, randomized comparative effectiveness trial, titled CARVTOP-ICD, evaluates the impact of carvedilol versus metoprolol succinate in patients with heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD). The study will enroll 2,000 participants across 100 U.S. sites and includes an 18-month feasibility phase with 100 participants from 15 sites. Eligible participants must be currently treated with metoprolol succinate and willing to switch to carvedilol, with randomization in a 1:1 ratio. Participants will be followed for up to 3 years, with regular assessments including ICD interrogations, medication adherence, healthcare utilization, and quality of life surveys. The primary endpoint is the first occurrence of any ICD therapy (appropriate or inappropriate), cardiovascular (CV) hospitalization, or CV death. Secondary endpoints include ICD shock burden, healthcare utilization, and patient-reported quality of life. The trial aims to provide high-quality comparative data to address clinical equipoise surrounding the two commonly used beta-blockers in HFrEF management.

Read the detailed description

The Comparative Effectiveness of Carvedilol versus Metoprolol Succinate in Heart Failure Patients with an Implantable Cardioverter Defibrillator (CARVTOP-ICD) study is a prospective, multicenter, open-label, two-arm, randomized clinical trial designed to assess the comparative effectiveness of carvedilol versus metoprolol succinate in patients with heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD). The study will enroll a total of 2,000 participants from 100 sites across the United States, with an initial feasibility phase enrolling 100 participants from 15 sites over 18 months.

The feasibility phase will assess study infrastructure, recruitment, consent processes, medication switching protocols, safety, adherence, and retention. A patient-centered approach, including engagement of caregivers and stakeholders, underpins this phase. Strategies to improve patient and provider participation, address barriers to beta-blocker switching, and ensure diversity in enrollment will be employed. Lessons learned will guide the full-scale study.

Eligible participants must have an ICD implanted for primary prevention of sudden cardiac death due to HFrEF (either ischemic or non-ischemic etiology), be currently treated with metoprolol succinate, and be willing to switch to carvedilol. Participants will be randomized 1:1 to either remain on metoprolol succinate or switch to an equivalent dose of carvedilol, with titration to maximally tolerated doses per protocol. Key exclusion criteria include treatment with any beta-blocker other than metoprolol succinate, systolic blood pressure \<100 mmHg, known intolerance to carvedilol, or inability to comply with the study protocol.

The primary endpoint is the first occurrence of any ICD therapy (appropriate or inappropriate), cardiovascular hospitalization, or cardiovascular death. Secondary endpoints include the burden of ICD shocks, healthcare utilization (including emergency visits and hospitalizations), and quality of life (QoL) measured by the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12), Florida Shock Anxiety Scale (FSAS), and Patient Health Questionnaire-2 (PHQ-2). Tertiary endpoints include specific analyses of ventricular tachyarrhythmias and atrial arrhythmias leading to inappropriate ICD therapies.

Participants will be followed for an average of 3 years. Assessments will be conducted at baseline, weeks 2 and 4, and quarterly thereafter. Study data will include standard of care tests such as cardiac imaging, ICD interrogations, laboratory measures (BNP/NT-proBNP, creatinine, BUN, potassium, sodium), NYHA classification, CV medication data, adverse events, protocol deviations, and patient-reported outcomes.

The study will also assess subgroup responses by sex, age, race/ethnicity, heart failure etiology (ischemic vs non-ischemic), ICD type (ICD vs CRT-D), and degree of LVEF impairment.

This PCORI-funded trial will generate robust, real-world evidence to guide clinical decision-making on beta-blocker choice in HFrEF patients with ICDs, addressing a significant gap in evidence and helping inform personalized treatment strategies to improve clinical and arrhythmic outcomes.

More information can be found at www.carvtop.org

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction (HFrEF)
  • Sudden Cardiac Death
  • Ventricular Arrhythmia
  • Implantable Cardioverter Defibrillator (ICD)
  • Beta-blocker Therapy
  • Cardiomyopathy

Keywords

  • arrhythmia
  • heart failure
  • ICD
  • implantable cardioverter defibrillator
  • ICD shock
  • carvedilol
  • metoprolol succinate
  • beta-blocker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • ICD implanted for primary prevention for HFrEF (either ICM or NICM) with remote monitoring capability
  • Current treatment with metoprolol succinate and willing to switch to carvedilol
  • \<50% during the past 12 months prior to consent

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to follow the protocol
  • Treatment with any other ßB than metoprolol succinate or no ßB treatment
  • Known prior intolerance or to carvedilol
  • Systolic blood pressure \<100 mmHg
  • Enrollment in another clinical trial
  • Inability or unwilling to consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Metoprolol Succinate Group

    Participants in this group will remain on their current treatment with metoprolol succinate. The dose of metoprolol succinate may be titrated to achieve recommended target doses as per the study protocol. The aim is to assess the outcomes associated with continued use of metoprolol succinate in patients with heart failure and an implantable cardioverter defibrillator (ICD).

    Drug: Metoprolol Succinate

  • Experimental
    Carvedilol Group

    Participants in this group will switch from metoprolol succinate to carvedilol at an equivalent dose. The dose of carvedilol will be titrated to the recommended target dose as per the study protocol. The goal is to evaluate the comparative effectiveness of carvedilol compared to metoprolol succinate in reducing cardiovascular events in patients with heart failure and an ICD.

    Drug: Carvedilol

Interventions

  • DrugMetoprololStudies of MetoprololMetoprolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Metoprolol succinate is a beta-blocker used for the management of heart failure with reduced ejection fraction (HFrEF). In this study, participants in the metoprolol succinate group will remain on their current treatment regimen with metoprolol succinate. The dose will be titrated to the recommended target dose as per the study protocol. The intervention aims to evaluate the effectiveness of continued use of metoprolol succinate in patients with heart failure and an implantable cardioverter defibrillator (ICD).

  • Carvedilol is a non-selective beta-blocker with alpha-blocking activity used in the treatment of heart failure. In this study, participants assigned to the carvedilol group will switch from metoprolol succinate to carvedilol at an equivalent dose. The carvedilol dose will be titrated to recommended target doses according to the study protocol. This intervention aims to compare the effectiveness of carvedilol versus metoprolol succinate in improving clinical outcomes in patients with heart failure and ICDs.

06

What researchers measure

Primary outcomes

  1. Composite Endpoint: First Occurrence of ICD Therapy, Cardiovascular Hospitalization, or Cardiovascular Death

    This composite outcome measures the time to first occurrence of one of the following events: (1) ICD therapy (appropriate or inappropriate shocks or anti-tachycardia pacing), (2) hospitalization due to cardiovascular causes, or (3) cardiovascular death. Only the first event occurring during the study period will be counted per participant.

    Time frame: Up to 3 years

Secondary outcomes

  1. Healthcare Utilization

    Total number of the following events during the study: all-cause hospital admissions, emergency department visits, and unplanned clinic visits. All events will be captured from electronic medical records.

    Time frame: Average of 3 years

  2. ICD Shock Burden

    Total number of ICD shocks (appropriate and inappropriate).

    Time frame: Average of 3 years

  3. Quality of Life - Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12)

    The KCCQ-12 is a 12-item self-administered questionnaire designed to assess the health status and quality of life in patients with heart failure. It evaluates symptoms, physical and social limitations, and overall quality of life. The total score ranges from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline, Year 1, Year 2, Year 3

  4. Quality of Life - Florida Shock Anxiety Scale (FSAS)

    The FSAS measures anxiety related to the possibility of receiving an ICD shock. It consists of 10 items, each rated on a 5-point Likert scale (1 = not at all, 5 = all of the time). Individual item scores are summed to produce a total score ranging from 10 to 50, with higher scores indicating greater shock-related anxiety.

    Time frame: Baseline, Year 1, Year 2, Year 3

  5. Quality of Life - Patient Health Questionnaire-2 (PHQ-2)

    The PHQ-2 is a 2-item screening tool that assesses depressive symptoms, focusing on anhedonia and depressed mood over the past two weeks. Each item is scored from 0 to 3, and the total score is the sum of the two items. Higher scores indicate greater severity of depressive symptoms.

    Time frame: Baseline, Year 1, Year 2, Year 3

07

Study locations

13 of 13 sites recruiting
08

References and documents

Publications

  • Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8. doi: 10.1056/NEJM200105313442201. PubMed 11386263 ↗
  • Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55. doi: 10.1056/NEJM199605233342101. PubMed 8614419 ↗
  • Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 Jul 5;362(9377):7-13. doi: 10.1016/S0140-6736(03)13800-7. PubMed 12853193 ↗
  • Diamond A, Goldenberg I, Younis A, Goldenberg I, Sampath R, Kutyifa V, Chen AY, McNitt S, Polonsky B, Steinberg JS, Zareba W, Aktas MK. Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients. JACC Clin Electrophysiol. 2023 Oct;9(10):2122-2131. doi: 10.1016/j.jacep.2023.06.009. Epub 2023 Aug 30. PubMed 37656097 ↗
  • Ruwald MH, Abu-Zeitone A, Jons C, Ruwald AC, McNitt S, Kutyifa V, Zareba W, Moss AJ. Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2013 Oct 8;62(15):1343-50. doi: 10.1016/j.jacc.2013.03.087. Epub 2013 Jun 13. PubMed 23770172 ↗
  • Ruwald MH, Ruwald AC, Jons C, Alexis J, McNitt S, Zareba W, Moss AJ. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Am Coll Cardiol. 2013 Apr 9;61(14):1518-26. doi: 10.1016/j.jacc.2013.01.020. PubMed 23500269 ↗
  • Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE, Pina IL, Whellan D, O'Connor CM. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol. 2012 Jul 17;60(3):208-15. doi: 10.1016/j.jacc.2012.03.023. Epub 2012 May 2. PubMed 22560018 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared for this study due to privacy concerns and the need to protect patient confidentiality. We will ensure that all results are reported in aggregate form while maintaining participant anonymity.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Jun 2031, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 9, 2025
StartActual
Aug 17, 2025
Primary completionEst.
Jun 1, 2031
CompletionEst.
Jul 1, 2031
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06964464
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Mehmet Aktas (Associate Professor - Department of Medicine, Cardiology (SMD), University of Rochester) — Principal investigator
First posted
May 9, 2025
Start date
Aug 17, 2025
Primary completion
Jun 1, 2031 (estimated)
Completion
Jul 1, 2031 (estimated)
Last update
Sep 18, 2025

Study contacts

Mehmet Aktas, M.D.
Contact
Mehmet_Aktas@URMC.Rochester.edu
585-275-5391
Nicole Guerrero, MBA
Contact
nicole.guerrero@heart.rochester.edu
0000000000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carvedilol

Start the discussion